Glomerulopathy due to dysproteinemia can have a wide spectrum of pathologic and clinical features based on specific characteristics of the abnormal protein and the response induced within the parenchymal tissue. Monoclonal immunoglobulin G (IgG) deposition can manifest as a different glomerular disease. Proliferative glomerulonephritis (GN) with monoclonal IgG deposits (PGNMID) is a unique entity mimicking immune complex GN that does not conform to any of those subtypes. IgG monoclonal granular deposition in the glomeruli with a pattern similar to immune complex disease suggested by C3 and C1q deposition should prompt consideration of PGNMID. Literature is scarce in terms of recurrence of disease in renal allografts. In this article we present the clinical-pathologic features of three cases of PGNMID in the renal allograft showing the variable course and manifestation of the disease.
Background
Various glomerular diseases can be caused by the deposition of monoclonal immunoglobulin G (IgG). Renal disease related to the deposition of monoclonal IgG containing both heavy and light chains can occur in type 1 cryoglobulinemia, Randall-type light-and heavy-chain deposition disease (LHCDD), light-and heavy-chain amyloidosis and immunotactoid glomerulonephritis [1] [2] [3] [4] [5] . Proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) is a relatively newly described entity mimicking immune complex glomerulonephritis (GN) that does not conform to any of those subtypes. It represents a form of proliferative GN with electron-dense deposits (EDDs) localized to glomeruli and immunofluorescence (IF) findings of monoclonal IgG deposits. Recurrent PGNMID in the renal allograft has been described in a few case series [6] [7] [8] . In this article we present the clinicalpathologic features of three cases of PGNMID in the renal allograft showing the variable course and manifestation of the disease. Our three cases, like most other reported cases, have no bone marrow involvement and no evidence of monoclonal protein on electrophoresis and immunofixation studies. Thus, this makes disease activity and remission status monitoring very difficult to assess.
Case 1
A 61-year-old Caucasian female developed end-stage kidney disease (ESKD) secondary to membranoproliferative glomerulonephritis (MPGN) based on a native kidney biopsy in 2001, with no further information about IF or electron microscopy (EM). In December 2006, her serum creatinine (SCr) was 530 μmol/L and she underwent a preemptive unrelated living kidney transplantation. In 2014, she was found to have a random urine protein/ gram creatinine (UPCR) of ∼452 mg/mmol and an SCr of 132 μmol/L, up from 106 μmol/L. Her workup for a lymphoproliferative disorder was negative, as was her serologic workup (see Table 1 ). On biopsy, IF showed diffuse granular positivity for IgG, C3 and C1q. Deposits were composed of IgG3-kappa with no Table 1 ). His kidney disease progressed and he declined therapy and restarted HD 9-month posttransplantation.
Case 3
A 40-year-old Hispanic female received a DDT in June 2001 after developing ESKD. In 1995, she had biopsy-proven type 1 MPGN. There were no IF data for reevaluation. In June 2012, she had hematuria and her SCr was 114 μmol/L, up from her baseline SCr of 97 μmol/L. UPCR was less than 20 mg/mmol. Her allograft biopsy showed a mesangioproliferative pattern of injury by light microscopy (see Table 1 ). IF revealed mesangial deposits restricted to IgG3-kappa. Her plasma cell dyscrasia workup was negative as was her serologic workup. SCr is stable at 115 μmol/L with UPCR at 10 mg/mmol.
Discussion
PGNMID, a novel type that does not conform to any subtypes, was described initially in 2004 [9] followed by the largest series of 37 cases in 2009 [10] . The disease manifests with proteinuria, hematuria and variable degrees of renal impairment. Disease incidence is 0.17% [10] . Most of the patients have a normal workup for paraproteinemia. Histologic patterns by light microscopy were mostly membranoproliferative with a lobular nodular pattern of injury followed by an endocapillary proliferative pattern. EM revealed granular, nonorganized deposits mostly in the mesangium and subendothelium. IF demonstrated granular glomerular deposits that stained for a single light-chain isotype and a single heavychain subtype, most commonly IgG3-kappa [7, 10] . More than 40 additional cases were identified by other groups [6, [11] [12] [13] [14] [15] [16] [17] [18] [19] . Recently, recurrent PGNMID after kidney transplantation has been reported as case reports or small series of one to four patients [6] [7] [8] . The recurrent disease manifested clinically as allograft dysfunction, hematuria and proteinuria. No patient had a detectable M spike in serum or urine. Complements were normal. Hepatitis B, hepatitis C and cryoglobulins were negative. Histologic features were mostly endocapillary proliferative GN or mesangial proliferative GN [7] .
Of the patients reported (see Table 1 ), the average age was 57 years. Patients tended to be Caucasian (11/12) and female (10/12). Disease diagnosis averaged 60 months from transplantation. The baseline SCr following transplantation was 128 μmol/L and at disease diagnosis was 246 μmol/L. IgG3-kappa was the predominant IgG identified (IgG3 11/12 and kappa 10/12). Three patients ended up with ESKD and two died related to infectious complications. There was an average of 24 months of follow-up after diagnosis.
Disease recurrence can range from an average of 3.8 months in some series [7] up to 2 years after kidney transplantation [5, 7] . The risk of recurrence is difficult to estimate based on the small number of patients and the absence of protocol biopsies in most cases. Moreover, the immunosuppressive treatment may have an impact on disease course that may be difficult to isolate. Disease recurrence can have a variable outcome, with some patients having persistent renal impairment and some progressing to end-stage renal disease. Our three cases reflect this variable disease course.
PGNMID is often missed or underdiagnosed, with diagnoses of MPGN or even light-and heavy-chain deposition disease (LHCDD). Some cases like case 1 and case 3 were originally diagnosed as MPGN type 1 before this entity was well established. In many instances, IF and EM were not available, nor was staining for light chains. PGNMID and LHCDD are similar in many aspects, however, the pathogenesis is different. LHCDD results from the deposition of heavy and light chains in the glomerular and tubular basement membrane, as opposed to PGNMID, where the deposits are intact monoclonal immunoglobulin affecting only the glomeruli. PGNMID is characterized by granular EDDs, in contrast to LHCDD, where those are mostly powdery deposits. IgG3 was the IgG isoform identified most often in prior studies to be deposited in the glomeruli despite comprising only 8% of the total immunoglobulin in the serum [6, 7] . Limitation to IgG3 in our three cases confirms the specific predilection for IgG3 to precipitate and self-aggregate in the glomeruli given its properties of high molecular weight, positive charge and complement activation capacity [7] .
Monoclonal gammopathy of renal significance is an increasingly recognized entity in patients who are found to have monoclonal protein with renal involvement. Patients who do not fulfill Case report and literature review | 727
the criteria for multiple myeloma have traditionally been labeled as monoclonal gammopathy of undetermined significance given the limited diagnostic schema, and consequently no therapy has been offered. However, it is more established now that addressing this clonal proliferation may preserve the kidneys and potentially prevent disease recurrence. There was no monoclonal protein identified in our patients, nor the other cases. Nevertheless, a thorough workup is strongly recommended as it may impact the therapeutic plan [20] .
Cases of de novo PGNMID on kidney allografts have been reported. One case series described the occurrence of PGNMID in two patients after transplantation. One patient with polycystic kidney disease was diagnosed with PGNMID 13 years after kidney transplantation. Another patient had diabetes nephropathy leading to ESKD and developed de novo PGNMID 3 years after transplantation [6] . While having different primary pathology supports that allograft disease is de novo, late occurrence does not exclude recurrence, as kidney transplant recipients may have a different disease course and disease activity due to immunosuppressive drugs.
Based on a pathogenesis hypothesis, it would seem rational to treat with immunomodulating therapy. Unfortunately, there is no proven effective treatment. Transplant recipients are on continuous immunosuppressive therapy. Aggressive immunosuppression with rituximab/or cyclophosphamide combined with steroids has been used [7] . Bortezomib was tried in one patient with native disease in one series [10] , however, not in any transplant patients. Given the role of monoclonal Ig in the disease pathogenesis, bortezomib was tried in two of our patients, one with disease in the native kidney prior to transplant (case 2) and one with disease recurrence following transplant (case 1), with no favorable response.
Conclusion
PGNMID is becoming a more recognized entity, with more patients being evaluated for renal transplant. This disease has a wide spectrum of clinical presentations. Distinguishing this entity from other diseases may have an impact on outcome and treatment. Evaluating these patients for transplant eligibility may be challenging in the absence of distinct data of remission given that most patients have normal bone marrow biopsy and no monoclonal band on serum and urine testing. Data are scarce in terms of follow-up and treatment. More long-term studies will be needed to further investigate disease course and response to therapy.
